TCR2 Therapeutics (TCRR) News Today → Gold Mania (From Stansberry Research) (Ad) Free TCRR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinePoseida Therapeutics Inc Ordinary Shares PSTXmorningstar.com - February 25 at 9:43 AMDICE Therapeutics Inc.wsj.com - June 20 at 11:13 PMAdaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Companyfinance.yahoo.com - June 1 at 4:46 PMmarketbeat.com - June 1 at 6:04 AMTCR2 Therapeutics Insider Trades Send a Signalbenzinga.com - May 16 at 1:36 PMRecap: TCR2 Therapeutics Q1 Earningsmsn.com - May 12 at 9:26 AM10-Q: TCR2 THERAPEUTICS INC.marketwatch.com - May 11 at 11:15 PMTCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - May 11 at 8:13 AMCompanies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite Riskyfinance.yahoo.com - April 15 at 12:05 PMMizuho Downgrades Tcr2 Therapeutics (TCRR)msn.com - March 25 at 7:55 PMTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho Securitiesmarkets.businessinsider.com - March 23 at 7:23 PMAnalysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)markets.businessinsider.com - March 23 at 2:23 PMTCR2 Therapeutics: TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 23 at 9:22 AMTCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - March 23 at 9:22 AMWhat To Know About Jefferies's Downgrade of TCR2 Therapeuticsmsn.com - March 9 at 5:14 PM4 Analysts Have This to Say About TCR2 Therapeuticsmarkets.businessinsider.com - March 9 at 12:14 PMTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at H.C. Wainwrightmarkets.businessinsider.com - March 8 at 8:52 PMShareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with Adaptimmunebenzinga.com - March 6 at 7:17 PMSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TCR² Therapeutics Inc. Buyoutbenzinga.com - March 6 at 7:17 PMWhy Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?investorplace.com - March 6 at 12:02 PMTCR2 Therapeutics: Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumorsfinanznachrichten.de - March 6 at 8:28 AMAdaptimmune To Combine With TCR² In All-stock Deal - Quick Factsmarkets.businessinsider.com - March 6 at 8:28 AMAdaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumorsfinance.yahoo.com - March 6 at 8:28 AMAdaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumorsfinance.yahoo.com - March 6 at 8:28 AMTCR2 Therapeutics Stock (NASDAQ:TCRR), Quotes and News Summarybenzinga.com - February 16 at 5:19 AMTCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023finance.yahoo.com - February 8 at 7:51 AMTCRR.C - | Stock Price & Latest News | Reutersreuters.com - January 18 at 10:44 AMSVB Securities Keeps Their Hold Rating on TCR2 Therapeutics (TCRR)markets.businessinsider.com - January 9 at 3:36 AMTCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com - January 5 at 5:59 PMTCR² Therapeutics Announces Pipeline Priorities for 2023finance.yahoo.com - January 5 at 12:59 PMTCR2 Therapeutics Inc. (TCRR)uk.finance.yahoo.com - January 2 at 2:28 PMTCRR TCR2 Therapeutics Inc.seekingalpha.com - December 16 at 11:34 PMTCR² Therapeutics to Present at the Piper Sandler Healthcare Conferencefinance.yahoo.com - November 23 at 8:25 AMDown 16.6% in 4 Weeks, Here's Why You Should You Buy the Dip in TCR2 Therapeutics Inc. (TCRR)finance.yahoo.com - November 11 at 3:27 PMTCR2 Therapeutics: TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updatefinanznachrichten.de - November 8 at 12:49 PMTCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 8 at 7:48 AMTCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancerfinance.yahoo.com - November 7 at 10:34 AMIs TCR2 Therapeutics (NASDAQ:TCRR) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - November 6 at 12:23 PMTCR2 Therapeutics Shares Jump After Additional Reponses in Ovarian Cancer, Mesotheliomafinance.yahoo.com - September 28 at 2:28 PMTCR2 Therapeutics stock rises 16% as cell therapy for solid tumors shows promise in trialseekingalpha.com - September 28 at 9:25 AMgavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesotheliomafinance.yahoo.com - September 28 at 9:25 AMTCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumorsfinance.yahoo.com - September 27 at 7:44 PMTCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summitfinance.yahoo.com - September 26 at 6:37 PMTCR2 Therapeutics (NASDAQ:TCRR) Price Target Cut to $18.00marketbeat.com - August 23 at 3:15 PMTCR² Therapeutics: Betting On A Solid Reversalseekingalpha.com - August 19 at 8:17 PMRoth Capital Reaffirms Buy Rating for TCR2 Therapeutics (NASDAQ:TCRR)marketbeat.com - August 10 at 11:04 AMTCR2 Therapeutics (NASDAQ:TCRR) Posts Quarterly Earnings Resultsmarketbeat.com - August 9 at 7:38 AMTCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 8 at 7:20 PMWhat Kind Of Shareholders Hold The Majority In TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) Shares?finance.yahoo.com - August 8 at 7:20 PMTCR2 Therapeutics Inc. (NASDAQ:TCRR) Given Average Rating of "Moderate Buy" by Brokeragesamericanbankingnews.com - August 8 at 1:33 AM Get TCR2 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRR and its competitors with MarketBeat's FREE daily newsletter. Email Address Gold Mania (Ad)Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite). See his free reveal right here. TCRR Media Mentions By Week TCRR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TCRR News Sentiment▼0.000.42▲Average Medical News Sentiment TCRR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TCRR Articles This Week▼00▲TCRR Articles Average Week Get TCR2 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LENZ Therapeutics News Aligos Therapeutics News Entera Bio News Genenta Science News Turnstone Biologics News Cidara Therapeutics News AVROBIO News Ikena Oncology News Elutia News Quince Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TCRR) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldThe only AI company you should be looking atBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TCR2 Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
